Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioLineRx Ltd. - American Depositary Shares (NQ: BLRX )

0.1252 +0.0206 (+19.69%)
Streaming Delayed Price Updated: 11:18 AM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioLineRx Ltd. - American Depositary Shares

< Previous 1 2 Next >
Bronstein, Gewirtz & Grossman, LLC Notifies BioLineRx Ltd. (BLRX) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioLineRx Ltd. (BLRX)
From Glancy Prongay & Murray LLP
Via Business Wire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A LONGSTANDING LAW FIRM, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, and Enovix and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Notifies BioLineRx Ltd. (BLRX) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioLineRx Ltd. (BLRX)
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of BioLineRx Ltd. (BLRX) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of BioLineRx Ltd. (BLRX) Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of BioLineRx Ltd. (BLRX) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of BioLineRx Ltd. (BLRX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of BioLineRx Ltd. (BLRX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
BIOLINERX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioLineRx Ltd. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
BLRX INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors to Secure Counsel Before Important Deadline in First Filed Securities Class Action Initiated by the Firm - BLRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against BioLineRx Ltd. (BLRX)
From Robbins LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of BioLineRx Ltd. (BLRX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of BioLineRx Ltd. Investors – BLRX
From The Rosen Law Firm, P.A.
Via Business Wire
TOP RANKED ROSEN LAW FIRM Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX
From The Rosen Law Firm, P.A.
Via Business Wire
NASDAQ:BLRX Shareholder Alert: Investigation over Potential Wrongdoing at BioLineRx Ltd.
San Diego, CA -- (SBWIRE) -- 11/16/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at BioLineRx Ltd. 
Via SBWire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX
From Rosen Law Firm
Via Business Wire
Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
Via FinancialNewsMedia
Accelerating R&D Activities in Breast Cancer Therapy Market Fueling Optimism for Development of Advanced Treatments
Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend... 
Via FinancialNewsMedia
Exposures COVID-19
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.